Some tips to help get started:
There are 420 active trials for advanced/metastatic non-small cell lung cancer. Click on a trial to see more information.
420 trials meet filter criteria.
Sort by:
HealthScout AI summary: Eligible patients are adults with stage IV, EGFR inhibitor-naive NSCLC harboring sensitizing EGFR mutations (exon 19 deletion or L858R) and good performance status, who receive single-agent osimertinib, an oral third-generation, irreversible EGFR tyrosine kinase inhibitor. The study includes mandatory tumor biopsies before treatment and at progression for genomic analysis.
ClinicalTrials.gov ID: NCT03586453
HealthScout AI summary: This trial enrolls adults with previously untreated metastatic or recurrent non-small cell lung cancer (NSCLC) without targetable mutations, testing two dosing regimens of subcutaneous nivolumab (a PD-1 inhibitor) in combination with intravenous ipilimumab (a CTLA-4 inhibitor) and standard chemotherapy. Patients must have measurable disease and good performance status, and those with untreated CNS metastases or active autoimmune disease are excluded.
ClinicalTrials.gov ID: NCT06946797
HealthScout AI summary: This trial enrolls adults with advanced or metastatic NSCLC, melanoma, endometrial cancer, or HNSCC who have progressed after standard therapies including prior anti-PD-1/L1 agents, and evaluates the combination of STC-15 (an oral METTL3 inhibitor targeting RNA methylation) plus toripalimab (anti-PD-1 antibody). Eligible patients must have measurable disease, ECOG 0–1, and no active CNS disease.
ClinicalTrials.gov ID: NCT06975293
HealthScout AI summary: This trial involves adults with unresectable locally advanced or metastatic NSCLC harboring active EGFR mutations, including C797S, who have progressed on osimertinib or another third-generation EGFR-TKI, receiving the investigational fourth-generation EGFR tyrosine kinase inhibitor H002 to assess its safety and preliminary anti-tumor activity.
ClinicalTrials.gov ID: NCT05519293
HealthScout AI summary: This trial evaluates ABSK112, a small molecule targeting EGFR exon 20 insertion mutations, in patients with locally advanced or metastatic non-small cell lung cancer characterized by these mutations, focusing on its safety, tolerability, and pharmacokinetics. The study involves dose escalation and an expansion cohort, enrolling adults with measurable disease and a life expectancy of at least three months.
ClinicalTrials.gov ID: NCT06225804
HealthScout AI summary: This trial involves patients with metastatic or recurrent non-small cell lung cancer who have progressed after platinum-doublet chemotherapy and PD-1/PD-L1 blockade, testing a combination therapy of pembrolizumab (anti-PD-1), ramucirumab (anti-VEGF receptor), and docetaxel.
ClinicalTrials.gov ID: NCT04340882
HealthScout AI summary: The trial involves adult patients with advanced or metastatic solid tumors, including those with non-small cell lung cancer (NSCLC), breast, and colorectal cancer, particularly focusing on NSCLC with EGFR mutations during dose expansion, testing CPO301, an EGFR-targeting antibody-drug conjugate.
ClinicalTrials.gov ID: NCT05948865
HealthScout AI summary: The trial targets patients with advanced NSCLC with EGFR mutations who have progressed after prior EGFR-TKI (including osimertinib) and/or platinum-based chemotherapy, assessing the safety and efficacy of JIN-A02, a fourth-generation EGFR tyrosine kinase inhibitor designed to overcome resistance related to EGFR mutations such as C797S.
ClinicalTrials.gov ID: NCT05394831
HealthScout AI summary: This trial involves patients with oligoprogressive non-small cell lung cancer who previously received first-line systemic therapies, evaluating the safety of adding the antimicrobial agent vancomycin to precision hypofractionated radiation therapy. Vancomycin, known for inhibiting bacterial cell wall synthesis, is used here to potentially reduce infections and modulate the immune response.
ClinicalTrials.gov ID: NCT03546829
HealthScout AI summary: The trial investigates the safety and efficacy of BMS-986449, an orally administered investigational drug, both as a monotherapy and in combination with the anti-PD-1 antibody nivolumab, in patients with advanced, unresectable, or metastatic solid tumors, with specific cohorts for non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).
ClinicalTrials.gov ID: NCT05888831